GSK, Pfizer gets CCI approval for consumer healthcare JV formation
After the deal, GSK will have a majority controlling equity interest of 68 per cent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 per cent.
New Delhi: The Competition Commission Friday said it has approved the formation of a joint venture for consumer healthcare products by pharmaceutical giants GlaxoSmithKline (GSK) and Pfizer.
GSK, in December 2018, had said it has reached an agreement with Pfizer to combine their consumer health businesses into a new joint venture (JV) with combined sales of around USD 12.7 billion (around Rs 88,900 crore).
The proposed combination involves the acquisition of Pfizer's consumer healthcare business by GSK, and the combination of GSK and Pfizer consumer healthcare business into a global consumer healthcare joint venture under the sole control of GSK, as per a notice submitted to CCI.
After the deal, GSK will have a majority controlling equity interest of 68 per cent in the combined consumer healthcare business, while Pfizer will have a minority non-controlling equity interest of the remaining 32 per cent.
In the consumer healthcare segment, GSK is active in research, development, manufacturing, and marketing of products which are typically available without a prescription (over-the-counter) for various indications.
On the other hand, Pfizer's consumer healthcare segment develops, manufactures and markets non-prescription medicines, vitamins, and nutritional products.
Read Also: Vaccine and blood thinner help drive Pfizer to quarterly earnings beat
GSK had said that the transaction is expected to close in the second half of 2019, subject to approval by its shareholders and certain antitrust authority approvals.
GSK is a British pharmaceutical company headquartered in London, whereas Pfizer is a US-based firm with headquarters in New York.
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd